A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.

Prior lines for metastatic disease, liver metastases, and PD‐1 inhibitors combined with chemotherapy and anti‐angiogenic therapy did not reach statistical significance in the multivariable analysis (Figure 10 ). 3.4.

also in 111,027 other papers